Not quite a game-changer, but at least a first step and another tool in the arsenal:
Merck and Ridgeback Biotherapeutics will seek emergency authorization for their drug, which they say could have “a profound impact in controlling the pandemic.”
www.cnbc.com
From what I've read in this article and some more online information, it looks this oral medication is slightly less effective than the monoclonal antibody infusions for the same treatment goals, although because the treatment is oral, it should prove much more scalable. Also, the window for treatment lasts much longer. The drug also uses a completely different mechanism from the monoclonal antibodies, so we could possibly combine the oral and IV treatments. I suspect the EAU, if granted, will restrict use to people with underlying risk factors, since they studied this population specifically.
The trials stopped at a rather low enrollment number of less than 1,000, so I could foresee some concern about possible safety issues arising after general release, especially because this drug takes advantage of a rather novel mechanism. However, further online sleuthing shows that the drug is not exactly new, and has been thoroughly studied as a possible influenza treatment (that trial apparently is still ongoing). Kind of like the mRNA vaccines, they were around for much longer than people realized, just not yet commercially released.
Tantalizingly, though, at the end of the article, they mention possible use to prevent spread among known COVID contacts. Used as a prophylactic, that could indeed end up as a game changer.